RESUMO
The study aimed to assess the human health risk of PM2.5-bound heavy metals from anthropogenic sources in Khon Kaen Province, Thailand between December 2020 and February 2021. According to the findings, the geometric mean concentration of PM2.5 in the university area, residential area, industrial zone, and the agricultural zone was 32.78 µg/m3, 50.25 µg/m3, 44.48 µg/m3, and 29.53 µg/m3, respectively. The results showed that the estimated human health risk assessment, in terms of non-carcinogenic risks among children and adults in an urban area (residential and university), industrial zone, and the agricultural area, was of hazard index (HI) value of >1.0 indicating a greater chance of chronic effects occurring. This study showed that exposure to PM2.5-bound heavy metal may increase the likelihood that lasting effects will result in a very high carcinogenic risk (CR) in children in residential areas, and an industrial zone with total carcinogenic risk (TCR) values of 0.23 × 10 1 , and 0.12 × 10 1 , respectively while resulting in a high TCR of 3.34 × 10 - 2 and 4.11 × 10 - 2 within the university areas and agricultural zone, respectively. In addition, health risk assessments among adults demonstrate high TCR values of 4.40 × 10 - 1 (residential area), 2.28 × 10 - 1 (industrial zone), and 7.70 × 10 - 3 (agricultural zone), thus indicating a potential health risk to adults living in these areas while the university area was very low effects on carcinogenic risk ( CR ≤ 10 - 8 ) for adults. Therefore, lowering the risk of exposure to PM2.5 via the respiratory tract, for example, wearing a mask outside is a very effective self-defense strategy for people within and around the study site. This data study strongly supports the implementation of the air pollutant emission source reduction measures control and health surveillance.
RESUMO
Spiders use their venom for defence and to capture prey. These venoms contain a cocktail of biologically active compounds that display several different biological activities, such as large molecules and small molecules including peptides, proteins/enzymes, and other components. Thus, venom constituents have attracted the attention of biochemists and pharmacologists over the years. The brown widow spider (Latrodectus geometricus) is a venomous spider found worldwide, including in Thailand. This spider causes human injuries, and the venom has many potential applications. In this study, we investigated the complexity and pharmacology of brown widow spider venom. Spider crude venom was investigated using partial proteome techniques and enzymatic activity, toxicity, and antibacterial activity assessments. We found that crude venom displayed a wide range of molecular masses from 19 to over 97 kDa, with molecular masses of 66 kDa intensely stained. Peptides and proteins were identified by liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS), which showed that the crude venom contained a variety of substances, including latrotoxins, apolipophorins, hemocyanins, chitinases, arginine kinase, allergen antigen 5-like protein, astacin-like metalloproteases, and serine proteases. High hyaluronidase activity was observed based on the turbidimetric method. The venom presented toxicity in crickets (PD50 = 0.73 ± 0.10 µg/g body weight), and substantial envenomation symptoms, such as slow-motion movement, paralysis, and even death, were noted. Moreover, this venom exhibited potential antibacterial activity against the gram-positive Bacillus subtilis but not the gram-negative Pseudomonas aeruginosa. Spider venom contains numerous molecules with biological activity, such as latrotoxins, which affect insects, and enzymes. In addition to latrotoxins, certain enzymes in venom are hypothesized to exhibit toxicity and antimicrobial activity. This study provides important information for the further development of natural compounds or insecticidal toxins.
RESUMO
The objectives of this study were to develop morphine sulfate sustained-release tablet formulations and to evaluate the bioequivalence compared with a commercial brand. The physicochemical properties of the formulated and commercial tablets were determined and compared. The bioequivalence investigation was carried out in 15 healthy male volunteers who received a single dose in a randomized two-way crossover design. After dosing, serial blood samples were collected for a period of 24 h. Morphine concentration was assayed by high-performance liquid chromatography with electrochemical detector. The log-transformed C(max) and AUC(s) were statistically compared by analysis of variance, and the 90% confidence intervals (CIs) of the ratio of the log-transformed C(max) and AUC(s) between the most promising developed formulation and the commercial product were determined. It was found that the dissolution rate profile of a developed formulation was similar to the commercial brand. Their similarity and difference factors were well within limits. In the bioequivalence study, the AUC(last) and AUC(inf) between the test and the reference products were not statistically different (p = 0.227 and p = 0.468, respectively), with the 90% CIs of 83.4-102.6% and 87.7-139.4%, respectively. However, the C(max) of the two formulations was significantly different (p = 0.019). The 90% CI of the developed formulation was 72.0-93.0% compared to the commercial product. In vitro dissolution of locally prepared morphine sulfate sustained-release tablets was comparable to commercial brand. However, the results justified the conclusion of lack of bioequivalence of the developed product to the commercial one.
